ZeClinics is an early-phase biopharma CRO using zebrafish for the discovery, safety and efficacy screenings of novel drugs and chemicals.
We combine our in-house technical expertise with a highly diversified portfolio to reduce by 10-fold our clients' time and cost requirements. Our services range from high-throughput screenings, cutting-edge CRISPR/cas9 gene-editing and phenotypic models.
ZeClinics has a global reach and yet a flexible approach: with corporate and academic clients across 4 continents within the drug discovery and agrochemical industry.
Wednesday, 18th November, 2020
10:00am GMT (UTC+0)
hosted by Lilly Xu, Ph.D. Senior Vice President, DMPK & Exploratory Toxicology Dept, ChemPartner